- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02707861
Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1
A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participants will enroll into one of two study cohorts. Cohort 1 will provide continued administration of IV ibalizumab for patients completing a prior ibalizumab clinical trial (TaiMed-sponsored or Investigator-Sponsored). Patients will continue to receive IV infusions of ibalizumab at the dosage assigned in the previous study - either 800 mg once every two weeks, or 2000 mg once every four weeks.
Cohort 2 will provide IV ibalizumab, 800 mg once every two weeks, for qualifying patients with multi-drug resistant HIV-1 and limited treatment options who have never previously received ibalizumab.
Participants may continue in this study for 48 weeks, or until ibalizumab becomes commercially available, whichever occurs first.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
San Juan, Puerto Rico, 00909
- Clinical Research PR, Inc.
-
-
-
-
California
-
Long Beach, California, United States, 90813
- Long Beach Education and Research Consultants
-
Los Angeles, California, United States, 90027
- Southern California Permanente Medical Group
-
Los Angeles, California, United States, 90036
- Ruane Clinical Research Institute Inc.
-
Los Angeles, California, United States, 90059
- Charles R. Drew University of Medicine and Science, Clinical and Translational Research Center
-
Los Angeles, California, United States, 90069
- Anthony Mills MD Inc.
-
Palm Springs, California, United States, 92262
- Palmtree Clinical Research, Inc.
-
San Francisco, California, United States, 94118
- Kaiser Foundation Research Institute
-
San Francisco, California, United States, 94115
- eStudy Site
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Yale University
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown University School of Medicine
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33316
- Gary Richmond, MD, PA
-
Miami, Florida, United States, 33133
- AIDS Healthcare Foundation - Kinder Medical Group
-
Miami, Florida, United States, 33140
- AIDS Healthcare Foundation - South Beach
-
Orlando, Florida, United States, 32803
- Orlando Immunology Center
-
West Palm Beach, Florida, United States, 33401
- Triple O Research Institute
-
-
Georgia
-
Atlanta, Georgia, United States, 30312
- AIDS Research Consortium of Atlanta
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- University of Hawaii - John A. Burns School of Medicine
-
-
Illinois
-
Chicago, Illinois, United States, 60613
- Howard Brown Health Center
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institute of Allergy & Infectious Diseases
-
-
Massachusetts
-
Springfield, Massachusetts, United States, 01105
- ID Research Institute
-
-
Missouri
-
Saint Louis, Missouri, United States, 63108
- Central West Clinical Research
-
-
New York
-
Bronx, New York, United States, 10461
- Jacobi Medical Center
-
New York, New York, United States, 10001
- AIDS Healthcare Foundation - Manhattan Midtown HCC
-
New York, New York, United States, 10011
- Chelsea Village Medical
-
-
North Carolina
-
Greenville, North Carolina, United States, 27834
- East Carolina University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Philadelphia FIGHT
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude's Children's Research Hospital
-
-
Texas
-
Bellaire, Texas, United States, 77401
- St. Hope Foundation Community Health Center
-
Dallas, Texas, United States, 75246
- North Texas Infectious Disease Consultants
-
Houston, Texas, United States, 77098
- Research Access Network
-
Houston, Texas, United States, 77098
- Crofoot Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
(Cohort 1)
- Currently receiving ibalizumab via other TaiMed-sponsored or investigator-Sponsored protocol
- Are capable of understanding and have voluntarily signed the informed consent document
(Cohort 2)
- 18 years of age or older
- Are capable of understanding and have voluntarily signed the informed consent document
- Have documented HIV-1 infection by official, signed, written history (e.g., laboratory report), otherwise an HIV-antibody test will be performed
- Are able and willing to comply with all protocol requirements and procedures
- Have a viral load >1,000 copies/mL and documented resistance to at least one antiretroviral medication from each of three classes of antiretroviral medications as measured by previous viral resistance testing (resistance testing is not provided by the study for qualification purposes)
- Have a history of at least 6 months on antiretroviral treatment
- Are receiving a failing antiretroviral regimen OR have failed and are off therapy
- Have viral sensitivity/susceptibility to at least one antiretroviral agent, other than ibalizumab, as determined by previous resistance test performed within 6 months of screening and be willing and able to be treated with at least one agent to which the patient's viral isolate is fully sensitive/susceptible according to the resistance tests used for screening as a component of OBR
- If sexually active, are willing to use an effective method of contraception during the study and for 30 days after the last administration of the study drug
Exclusion Criteria:
(Cohort 1)
- There are no Exclusion Criteria for patients meeting the Inclusion Criteria for Cohort 1
(Cohort 2)
- Eligible for participation in other TaiMed-sponsored clinical trials of ibalizumab
- Any significant diseases (other than HIV-1 infection) or clinically significant findings, including psychiatric and behavioral problems, determined from screening, medical history and/or physical examination that, in the investigator's opinion, would preclude the patient from participating in this study
- Any significant acute illness within 1 week before the first administration of investigational medication on this study
- Any active infection secondary to HIV requiring acute therapy; however, patients that require maintenance therapy (i.e., secondary prophylaxis for opportunistic infections) will be eligible for the study.
- Any immunomodulating therapy (including interferon), systemic steroids, or systemic chemotherapy within 4 weeks before Day 0
- Any prior exposure to ibalizumab (formerly TNX-355 and Hu5A8)
- Any vaccination within 7 days before Day 0
- Any female patient who either is pregnant, intends to become pregnant, or is currently breastfeeding
- Any current alcohol or illicit drug use that, in the investigator's opinion, will interfere with the patient's ability to comply with the study schedule and protocol evaluations
- Any previous clinically significant allergy or hypersensitivity to any excipient in the ibalizumab formulation
- Any radiation therapy during the 28 days before first administration of investigational medication on this study
Any clinically significant Grade 3 or 4 laboratory abnormality according to the Division of AIDS (DAIDS) grading scale, except for the following asymptomatic Grade 3 events:
- triglyceride elevation
- total cholesterol elevation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1
IV ibalizumab (combined with optimized background regimen): 800 mg once every two weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial OR 2000 mg once every four weeks for patients receiving that dosage on prior, successfully completed ibalizumab clinical trial Administered for 48 weeks, or until ibalizumab becomes commercially available |
Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry
Other Names:
An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing.
The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).
Other Names:
|
Experimental: Cohort 2
IV ibalizumab (combined with optimized background regimen): 800 mg once every two weeks for qualifying patients who have never received ibalizumab Administered for 48 weeks, or until ibalizumab becomes commercially available |
Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry
Other Names:
An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing.
The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability of Ibalizumab + OBR
Time Frame: Through 48 weeks
|
Number of participants with Grade 3/4 adverse events possibly, probably, or definitely due to ibalizumab
|
Through 48 weeks
|
Discontinuations Due to Adverse Events Related to Ibalizumab
Time Frame: 48 weeks
|
number of participants discontinuing ibalizumab treatment due to adverse events probably, possibly, or definitely related to ibalizumab
|
48 weeks
|
Effectiveness of Ibalizumab + OBR (Cohort 2 Only)
Time Frame: 7 days
|
Number of patients in Cohort 2 achieving at least a 0.5 log change from Baseline in viral load at Day 7 of the study
|
7 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Suppression to <50 Copies With Ibalizumab + OBR (Cohort 2 Only)
Time Frame: 48 weeks
|
Number of patients in Cohort 2 with HIV-1 RNA levels <50 copies/mL at week 48
|
48 weeks
|
Suppression to <400 Copies by Ibalizumab + OBR (Cohort 2 Only)
Time Frame: 48 weeks
|
Number of patients in Cohort 2 with HIV-1 RNA levels <400 copies/mL at week 48
|
48 weeks
|
Effectiveness of Ibalizumab + OBR by 1.0 Log10 Decrease in Viral Load From Baseline (Cohort 2 Only)
Time Frame: 48 weeks
|
Number of patients in Cohort 2 achieving at least a 1.0 log10 decrease in viral load from Baseline measurement at all assessment time points
|
48 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stanley T. Lewis, MD, MPH, TaiMed Biologics Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TMB-311
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Hospital Clinic of BarcelonaCompletedIntegrase Inhibitors, HIV; HIV PROTEASE INHIBSpain
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
Clinical Trials on ibalizumab
-
TheratechnologiesICON Clinical Research; Excelsus Statistics Inc.; Health Psychology Research...RecruitingHIV Infections | Multi-Antiviral ResistanceUnited States
-
TaiMed Biologics Inc.WestatCompletedHIV-1-infectionUnited States
-
David HoUS Military HIV Research Program; Henry M. Jackson Foundation for the Advancement... and other collaboratorsRecruitingHIV-1-infectionTanzania
-
Kaiser PermanenteTaiMed Biologics Inc.Completed
-
TaiMed Biologics Inc.CompletedHIVUnited States, Taiwan, Puerto Rico
-
EpividianTheratechnologies; FIECONCompletedHIV-1-infectionUnited States
-
TaiMed Biologics Inc.Bill and Melinda Gates Foundation; Aaron Diamond AIDS Research CenterCompletedPrevention of Infection With HIV-1United States
-
TanoxUnknownHIV InfectionsUnited States, Puerto Rico, Canada
-
TaiMed Biologics Inc.CompletedHIVPuerto Rico, United States
-
University of Colorado, DenverNo longer availableHuman Immunodeficiency Virus (HIV)United States